RBL LLC has welcomed Devyn Smith to its board, a move set to enhance biotech ventures from Rice University by accelerating groundbreaking therapies.

RBL LLC has launched Duracyte, a revolutionary biotech company creating implantable devices to continuously produce therapeutic proteins in patients' bodies.

RBL LLC has appointed Chris Duke as operating partner, bringing rich experience in biopharmaceuticals to enhance biotech venture creation, focusing on breakthrough medical technologies.

RBL LLC's new spin-off, SteerBio, has launched with $18.2 million in federal funding for a novel therapy targeting lymphedema, aiming to change patient lives.

RBL LLC announces a strategic investment from Carnrite Ventures, aimed at accelerating biotech innovations and developing groundbreaking medical technologies.

RBL LLC has received strategic investment from Modi Ventures, set to accelerate the growth of biotech startups and enhance the development of medical technologies.

Mark Hensley has joined RBL LLC as a senior adviser, aiming to accelerate the development of groundbreaking life sciences technologies.

RBL LLC has appointed James Watson to its board of directors, enhancing its leadership and commitment to advancing biotech innovations and therapies.

RBL LLC has launched Sentinel BioTherapeutics, a clinical-stage company, at the ASCO 2025 meeting, showcasing its innovative cancer therapies.

Researchers at Rice University have developed an ingenious implant that can effectively target and treat challenging cancers like melanoma and more.

Join us on May 5 for the grand opening of RBL LLC at the Rice Biotech Launch Pad. Hear from industry leaders Robert Langer and Robert Ruffolo.